Menu

Close

Sign InSign Out

Materials

Co-pay Cards & Patient Savings Offers

Request Samples

Hospital Products

Vaccines, Biologics & ​​​​​​​Small-molecule Medicines

Pfizer Oncology Together

Pfizer RxPathways

Events

Materials

Videos

Menu

Close

About

Burden of IPD

Dosing

Dosing

Administration and implementation

Efficacy & Safety

Efficacy

Safety Profile

Immunogenicity

​​​​​​​ Support & Order

Videos

Materials

Order Prevnar 13®

Adherence

Resources

Events

Burden of IPD

Clinical syndromes

There are 3 major clinical syndromes of IPD: meningitis, bacteremia, and bacteremic pneumonia1

The most common ways IPD can present in your practice include1:

** This is an optional area where footnotes can live.

Bacteremic pneumonia accounts for 12%-16% of IPD in children ≤2 years of age1​​​​​​​

  • Streptococcus pneumoniae is the most common cause of community-acquired cases of bacteremic pneumonia2

Bacteremic pneumonia can pose serious risks of complications in infants and younger children3

  • Bacteremic pneumonia can present clinically in children as severe respiratory distress requiring mechanical ventilation and can lead to respiratory failure, pleural effusions, pleural empyema, and meningitis3

References:
  1. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. In: Hamborsky J, Kroger A, Wolfe S, eds. 13th ed. Washington, DC: Public Health Foundation; 2015:275-296.
  2. Fritz CQ, Edwards KM, Self WH, et al. Prevalence, risk factors, and outcomes of bacteremic pneumonia in children. Pediatrics. 2019;144(1):e20183090.
  3. ​​​​​​​Tan TQ. Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines. Clin Microbiol Rev. 2012;25(3):409-419. doi:10.1128/CMR.00018-12.

Dosing

Review the CDC-recommended dosing schedule for Prevnar 13®

View now

Impact of late doses

Get the facts

Order from Pfizer Prime

To stock Prevnar 13®, call 1-800-666-7248 or click here

Order now

PREVNAR 13® is a registered trademark of Wyeth LLC.
Manufactured by Wyeth Pharmaceuticals Inc.
© 2021 Pfizer Inc.
  • Severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 13® or any diphtheria toxoid–containing vaccine is a contraindication
  • Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant's medical status, and the potential benefits and risks
  • In infants and toddlers, the most commonly reported serious adverse events were bronchiolitis (0.9%), gastroenteritis (0.9%), and pneumonia (0.9%)
  • In children 6 weeks through 17 years, the most commonly reported solicited adverse reactions were injection site tenderness, redness, or swelling, irritability, decreased appetite, decreased or increased sleep, and fever
  • In children 6 years through 17 years of age, Prevnar 13® is administered as a single dose

Patients should always ask their doctors for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). ​​Visit www.vaers.hhs.gov or call 1-800-822-7967.

Please see full Prescribing Information for Prevnar 13®.

  • Prevnar 13® is a vaccine indicated for active immunization for the prevention of disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F
  • In children 6 weeks through 17 years for invasive disease caused by the 13 serotypes, and for children 6 weeks through 5 years of age for otitis media caused by 7 of the 13 serotypes only (4, 6B, 9V, 14, 18C, 19F, and 23F)​​​​​​​

Limitations of Use and Effectiveness

  • Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine

IndicationS

  • Prevnar 13® is a vaccine indicated for active immunization for the prevention of disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F​​​​​​​​​​​​​​
  • In children 6 weeks through 17 years for invasive disease caused by the 13 serotypes, and for children 6 weeks through 5 years of age for otitis media caused by 7 of the 13 serotypes only (4, 6B, 9V, 14, 18C, 19F, and 23F)
    ​​​​​​​

Limitations of Use and Effectiveness

  • Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine

Please see full Prescribing Information.

OK. We'll need you to sign in before we can determine if you are aligned with a sales  representative. 

If you select 'Yes', you will be required to enter your username and password in the sign-in form  that will appear over this window.

Would you like to sign in now?